English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Inverse but not full benzodiazepine agonists modulate recombinant α6β2γ2 GABAA receptors in transfected human embryonic kidney cells

MPS-Authors
/persons/resource/persons92842

Ewert,  Markus
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

/persons/resource/persons95292

Seeburg,  Peter H.
Department of Molecular Neurobiology, Max Planck Institute for Medical Research, Max Planck Society;

Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Kleingoor, C., Ewert, M., von Blankenfeld, G., Seeburg, P. H., & Kettenmann, H. (1991). Inverse but not full benzodiazepine agonists modulate recombinant α6β2γ2 GABAA receptors in transfected human embryonic kidney cells. Neuroscience Letters, 130(2), 169-172. doi:10.1016/0304-3940(91)90389-B.


Cite as: http://hdl.handle.net/21.11116/0000-0000-6F09-B
Abstract
We compared the modulation of GABA (γ-aminobutyric acid)-activated currents by benzodiazepines in recombinant (GABAA receptors containing either one of two α subunits, α1 or α6. Lüddens et al. (Nature, 346 (1990) 648–651) have previously demonstrated that the α6 subunit is part of a cerebellar receptor subtype which selectively binds Ro15–4513, an antagonist of alcohol-induced motor ataxia. Here we report that the imidazobenzodiazepine Ro15–4513 (ethyl 8-azido-5,6-dihydro-5-methyl-6-oxo-4H-imidazo-(1,5-a) (1,4)benzodiazepine-3-carboxylate) reduced GABA-activated currents in recombinant α6β2γ2 and α1β2γ2 receptors, thus acting consistently as an inverse agonist. Moreover, another well characterized negative modulator, DMCM (methyl-4-ethyl-6,7-dimethoxy-β-carboline-3-carboxylate), also reduces GABA activated-currents in both receptors. In contrast, flunitrazepam (FNZM), a benzodiazepine agonist, increases GABA-activated currents in α1β2γ2 receptors, but not in α6β2γ2 receptors. This study lends further support to the hypothesis that the binding sites of full and partial inverse agonists are different.